New hormone protocol could make IVF cheaper and easier for women with low egg supply

NCT ID NCT05847283

Recruiting now Disease control Sponsor: Tam Anh TP. Ho Chi Minh General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using the hormone dydrogesterone (taken as a pill) alongside standard fertility injections can help women with low ovarian reserve collect more eggs for IVF. The trial compares this approach to the usual GnRH antagonist protocol. Researchers will track pregnancy rates after the first embryo transfer in 730 women aged 18-37.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dydrogesterone (oral hormone) and human menopausal gonadotrophin (hMG) injections
What this could lead to: If successful, this could offer a more affordable and patient-friendly way to collect eggs for IVF in women with low ovarian reserve, potentially improving pregnancy chances.
What could go wrong: This is a Phase 2/3 trial with 730 participants, but results may not apply to all women. The protocol may not significantly improve egg quality or pregnancy rates, and side effects from hormones are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIMINISHED OVARIAN RESERVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian dysfunction primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIMINISHED OVARIAN RESERVE

Contacts and locations

Locations

IVFTA
RECRUITING

Hanoi, Hanoi, 100000, Vietnam
Ivfta Hcmc
RECRUITING

Ho Chi Minh City, Ho Chi Minh, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.